Ellipsys Medical has filed a notice of an exempt offering of securities to raise $10,850,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Ellipsys Medical is raising up to $10,850,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Ellipsys Medical
Ellipsys Medical is dedicated to advancing vascular access technologies that improve patient outcomes in end-stage renal disease. The company partners with clinicians and health systems to deliver solutions that enhance care quality, streamline workflows, and support long-term access durability. The Ellipsys System enables physicians to create a percutaneous AV fistula using a single catheter under ultrasound guidance. The procedure can be performed in multiple care settings and is designed to reduce the need for surgical incisions, implants, and vessel manipulation.

To learn more, visit https://ellipsysmedical.com/
LinkedIn: https://www.linkedin.com/company/ellipsysmedical/

Contact:
Frank Hettmann, President
https://www.linkedin.com/in/frankhettmann/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.